FDA To Scrutinize MDS Pharma Bioequivalence Study Methods
This article was originally published in The Pink Sheet Daily
Executive Summary
CRO’s approach to investigating sources of contamination in bioequivalence studies is “inadequate,” the agency says in an “untitled” letter. MDS says it is “actively working to address the agency’s concerns.”